Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Erdei

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Journal of Immunological Methods|October 18, 2011
Characterization of factors influencing on-chip complement activation to optimize parallel measurement of antibody and complement proteins on antigen microarraysKrisztián Papp, Péter Végh, Renáta Hóbor, et al.
Immunology Letters|May 31, 2017
The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytesSzilvia Lukácsi, Zsuzsa Nagy-Baló, Anna Erdei, et al.
Biosensors & Bioelectronics|July 6, 2021
Label-free real-time monitoring of the BCR-triggered activation of primary human B cells modulated by the simultaneous engagement of inhibitory receptorsKristof Kliment, Inna Szekacs, Beatrix Peter, et al.
Immunology Letters|February 26, 2014
Coadministration of antigen-conjugated and free CpG: effects of in vitro and in vivo interactions in a murine modelMelinda Herbáth, Zsuzsanna Szekeres, Dorottya Kövesdi, et al.
International Immunology|September 11, 2012
Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patientsMariann Kremlitzka, Anna Polgár, Lívia Fülöp, et al.
Rheumatology (Oxford, England)|August 26, 2010
Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr miceKrisztián Papp, Péter Végh, Andrey Tchorbanov, et al.
Immunobiology|August 22, 2012
CR3 is the dominant phagocytotic complement receptor on human dendritic cellsNoémi Sándor, Katalin Kristóf, Katalin Paréj, et al.
Molecular & Cellular Proteomics : MCP|October 31, 2006
On-chip complement activation adds an extra dimension to antigen microarraysKrisztián Papp, Zsuzsanna Szekeres, Nóra Terényi, et al.
Frontiers in Immunology|April 19, 2021
Revisiting the Coreceptor Function of Complement Receptor Type 2 (CR2, CD21); Coengagement With the B-Cell Receptor Inhibits the Activation, Proliferation, and Antibody Production of Human B CellsKristóf G Kovács, Bernadett Mácsik-Valent, János Matkó, et al.
Molecular Immunology|September 7, 2011
Modulation of the humoral immune response by targeting CD40 and FcγRII/III; delivery of soluble but not particulate antigen to CD40 enhances antibody responses with a Th1 biasZsuzsanna Szekeres, Melinda Herbáth, Zoltán Szittner, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Journal of Immunological Methods|October 18, 2011
Characterization of factors influencing on-chip complement activation to optimize parallel measurement of antibody and complement proteins on antigen microarraysKrisztián Papp, Péter Végh, Renáta Hóbor, et al.
Immunology Letters|May 31, 2017
The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytesSzilvia Lukácsi, Zsuzsa Nagy-Baló, Anna Erdei, et al.
Biosensors & Bioelectronics|July 6, 2021
Label-free real-time monitoring of the BCR-triggered activation of primary human B cells modulated by the simultaneous engagement of inhibitory receptorsKristof Kliment, Inna Szekacs, Beatrix Peter, et al.
Immunology Letters|February 26, 2014
Coadministration of antigen-conjugated and free CpG: effects of in vitro and in vivo interactions in a murine modelMelinda Herbáth, Zsuzsanna Szekeres, Dorottya Kövesdi, et al.
International Immunology|September 11, 2012
Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patientsMariann Kremlitzka, Anna Polgár, Lívia Fülöp, et al.
Rheumatology (Oxford, England)|August 26, 2010
Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr miceKrisztián Papp, Péter Végh, Andrey Tchorbanov, et al.
Immunobiology|August 22, 2012
CR3 is the dominant phagocytotic complement receptor on human dendritic cellsNoémi Sándor, Katalin Kristóf, Katalin Paréj, et al.
Molecular & Cellular Proteomics : MCP|October 31, 2006
On-chip complement activation adds an extra dimension to antigen microarraysKrisztián Papp, Zsuzsanna Szekeres, Nóra Terényi, et al.
Frontiers in Immunology|April 19, 2021
Revisiting the Coreceptor Function of Complement Receptor Type 2 (CR2, CD21); Coengagement With the B-Cell Receptor Inhibits the Activation, Proliferation, and Antibody Production of Human B CellsKristóf G Kovács, Bernadett Mácsik-Valent, János Matkó, et al.
Molecular Immunology|September 7, 2011
Modulation of the humoral immune response by targeting CD40 and FcγRII/III; delivery of soluble but not particulate antigen to CD40 enhances antibody responses with a Th1 biasZsuzsanna Szekeres, Melinda Herbáth, Zoltán Szittner, et al.
Pageof 10